Pharmacokinetic?pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide

Pathogenesis of dyskinesias in parkinson's disease

M. Maral Mouradian, Isabella J.E. Heuser, Fabio Baronti et al. · Annals of Neurology · 1989 · 161 citations

Abnormal Involuntary Movements, Motor Dysfunction, Neurophysiology +15

Preventing levodopa-induced dyskinesias.

C W Olanow, José Á. Obeso · PubMed · 2000 · 137 citations

Neurological Disorder, Neurotransmitter, Dopamine Receptors +17

A Double-Blind Pharmacokinetic and Clinical Dose—Response Study of Entacapone as an Adjuvant to Levodopa Therapy in Advanced Parkinson's Disease

Hanna Ruottinen, U. K. Rinne · Clinical Neuropharmacology · 1996 · 127 citations

Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone

T. Ker�nen, A. Gordin, MariAnne Karlsson et al. · European Journal of Clinical Pharmacology · 1994 · 126 citations

Soluble Catechol-o-methyltransferase, Intravenous Administration, Pharmacological Study +6

The effect of L‐leucine on the absorption of levodopa, studied by regional jejunal perfusion in man.

Hans Lennernäs, Dag Nilsson, Aquilonius Sm et al. · British Journal of Clinical Pharmacology · 1993 · 116 citations · Full text